je.st
news
Tag: medicines
Confusion Increasing over Animal Medicines in Livestock
2015-03-27 01:00:00| ThePigSite - Industry News
UK - The majority of shoppers in the UK believe growth hormones are used by farmers to make animals for food grow faster and that antibiotics used in livestock make them less effective for people.
Tags: increasing
animal
confusion
livestock
J&J pleads guilty, pays $25m over manufacturing adulterated infants', children's OTC medicines
2015-03-11 07:19:42| Food - Topix.net
J&J subsidiary McNeil-PPC on Tuesday pleaded guilty to violating the federal Food, Drug and Cosmetic Act due to contamination and manufacturing issues related to its OTC infants' and children's liquid medications, including Infants' Tylenol, Children's Tylenol and Children's Motrin. McNeil was charged by the US Attorney's Office in the Eastern District of Pennsylvania with introducing interstate commerce drugs that were deemed adulterated, which is a misdemeanor.
Tags: pays
manufacturing
guilty
infants
KEYTRUDA (pembrolizumab) is First Medicine to be Made Available to Patients Through U.K. Early Access to Medicines Scheme (EAMS) for Advanced Melanoma
2015-03-11 01:01:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. EAMS Aims to Give U.K. Patients Access to Promising, Innovative Treatments Prior to European License KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the companys anti-PD-1 therapy, pembrolizumab, which is marketed in the U.S. under the name KEYTRUDA, is the first treatment to be accepted under the U.K.s new Early Access to Medicines Scheme (EAMS). Pembrolizumab was accepted under the scheme for the treatment of advanced melanoma based on the significance of the early study findings and unmet medical need. Language: English Contact: MerckMedia Contacts:Pam Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestor Contacts:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Merck Announces Collaboration with the Medicines Patent Pool to Expand Access to Pediatric Formulations of Raltegravir in Developing Countries
2015-02-24 09:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced an agreement with the Medicines Patent Pool (MPP) to license its pediatric formulations of raltegravir for use in treating HIV-1 infection in infants and children from four weeks to under 12 years of age in developing countries. This is the MPPs first agreement to provide access to an HIV integrase inhibitor for use in combination HIV therapy for infants and children in this age range. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Ian McConnell, 908-740-1921orInvestors:Joe Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: access
countries
expand
pool
Ensure Your Medicine's Stability While Saving Money Visit Multisorb at Pharmapack Europe
2015-02-10 11:31:39| Industrial Newsroom - All News for Today
Buffalo, New York Multisorb Technologies will join more than 350 international exhibitors, February 11-12, 2015, in Paris, France, for Pharmapack Europe. During this widely attended European exhibition, Multisorb will showcase its innovative sorbent technology and industry leading products. Leading the drive for...
Tags: visit
money
europe
ensure
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] next »